Therefore, several phase II and III clinical trials (e.g., NEJ043, APPLE (WJOG11218L), IMpower 151, ORIENT‐31 and ATTLAS (KCSG‐LU19‐04), etc.)have explored the therapeutic potential of combining anti‐angiogenic agents with immune‐chemotherapy in patients with EGFR‐mutated NSCLC who have progressed on EGFR TKIs.18, 19, 21, 22, 23, 24. This evidence concerns the gene EGFR and non-small cell lung carcinoma.